Bicara announces preliminary data from Phase 1b cohort of ficerafusp alfa

Bicara Therapeutics (BCAX) presented preliminary data from a Phase 1b expansion cohort evaluating 750 mg of ficerafusp alfa weekly in combination with pembrolizumab in first-line human papillomavirus-negative recurrent/metastatic head and neck squamous cell carcinoma, HNSCC. The data were highlighted in an oral presentation by Deborah Wong, MD, PhD of UCLA Medical Center at the European Society for Medical Oncology, ESMO, Asia Congress and will be discussed on a company conference call and webcast today, December 6. Phase 1/1b expansion cohort data presented at ESMO Asia show that 750mg ficerafusp alfa in combination with pembrolizumab was generally well-tolerated, with a safety profile consistent with the known safety profile of ficerafusp alfa plus pembrolizumab in R/M HNSCC. At a preliminary duration of follow-up, 750 mg of ficerafusp alfa demonstrated a 57% confirmed overall response rate, with 10% of patients achieving a completed response, and 29% of responders demonstrating deep responses of at least 80% tumor shrinkage.